Revenue
41.1 thousand iso4217-usd
2019 Q3 · iso4217-usd
Exact inputs and evidence
- Revenue: 41106 iso4217-usd Source
Fundies. English
PLx Pharma Inc.
EDGAR76 filing records in this dataset, filed from 2014-02-06 to 2022-11-10. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-8,943.31%
2019-09-30 · %
Operating cash flow
-3.16 million iso4217-usd
2019 Q3 · iso4217-usd
Free cash flow
-3.29 million iso4217-usd
2019 Q3 · iso4217-usd
- Cash and cash equivalents
- 25.8 million USD Source
Exact value
25834000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 29.1 million shares Source
Exact value
29137692 shares
Reported share-count change
6.04% · 1.66 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
829 thousand iso4217-usd
2018-10-01 – 2019-09-30
Exact inputs and evidence
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2022-11-10.
Financial data available through: 2021-12-31.
Coverage by financial measure
- Revenue: 3 of 11 periods available· newest 2018-12-31
- Operating income: 4 of 11 periods available· newest 2021-12-31
- Net income: 7 of 11 periods available· newest 2021-12-31
- Operating cash flow: 4 of 11 periods available· newest 2021-12-31
- Capital expenditure: 4 of 11 periods available· newest 2020-12-31
- Total assets: 5 of 11 periods available· newest 2021-12-31
- Total liabilities: 5 of 11 periods available· newest 2021-12-31
- Current assets: 5 of 11 periods available· newest 2021-12-31
- Current liabilities: 2 of 11 periods available· newest 2021-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2021-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 4 of 11 periods available· newest 2021-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 30.91 millionPrior period
−USD 15.21 million
–
Current period
−USD 46.13 million
–
Exact inputs and evidence
-46125000 − -15211000 = -30914000 USD
-15211000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source-46125000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 19.88 millionPrior period
−USD 12.24 million
–
Current period
−USD 32.12 million
–
Exact inputs and evidence
-32118000 − -12243000 = -19875000 USD
-12243000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source-32118000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2018 2018-01-01 – 2018-12-31
- Revenue iso4217-usd 753,108 100% of revenue
- Operating costs Derived Unavailable An input is unavailable.
- Operating income Unavailable An input is unavailable.
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow Unavailable An input is unavailable.
- Capital expenditure iso4217-usd 654,870 87% of revenue
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 Not shown: operating income or net income is not reported.
- 2017 Not shown: operating income or net income is not reported.
- 2018 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 20000 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
| 2017 2017-01-01 – 2017-12-31 | 778657 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
| 2018 2018-01-01 – 2018-12-31 | 753108 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
Amounts are exact, in iso4217-usd.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
iso4217-usd 753.1K 2018
Values and sources
| Period | Series | Value(iso4217-usd) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 20000 |
|
| 2017 | Revenue | 778657 |
|
| 2018 | Revenue | 753108 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
-3.3% 2018
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | No prior comparable period |
|
| 2017 | Year over year | 3,793.3% |
|
| 2018 | Year over year | -3.3% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016-12-31 | Operating margin | Not reported |
|
| 2017-12-31 | Operating margin | Not reported |
|
| 2018-12-31 | Operating margin | Not reported |
|
| 2016-12-31 | Net margin | Not reported |
|
| 2017-12-31 | Net margin | Not reported |
|
| 2018-12-31 | Net margin | Not reported |
|
| 2016 | Free cash flow margin | Not reported |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(iso4217-usd) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | Not reported | No source recorded |
| 2017 | Operating cash flow | Not reported | No source recorded |
| 2018 | Operating cash flow | Not reported | No source recorded |
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(iso4217-usd) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | Unavailable | No source recorded |
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2017-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2018-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2017-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2018-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2011 2011-01-01 – 2011-12-31 | −USD 1.96 million Exact valueExact value: -1964494 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period. |
| 2012 2012-01-01 – 2012-12-31 | −USD 1.84 million Exact valueExact value: -1843986 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period. |
| 2013 2013-01-01 – 2013-12-31 | −USD 4.01 million Exact valueExact value: -4013620 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Operating cash flow + Capital expenditure is unavailable for this period. |
| 2015 2015-01-01 – 2015-12-31 | −USD 18.74 million Exact valueExact value: -18742706 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 14.59 million Exact valueExact value: -14592517 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2016 2016-01-01 – 2016-12-31 | −USD 21.32 million Exact valueExact value: -21321129 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 15.58 million Exact valueExact value: -15583161 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 15.21 million Exact valueExact value: -15211000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.24 million Exact valueExact value: -12243000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 46.13 million Exact valueExact value: -46125000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 32.12 million Exact valueExact value: -32118000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
76 filings · 2,178 latest values · 2,178 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001497504, 1497504, DPRX, PLXP, edgar:1497504, plxp
Also known as Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC, PLX PHARMA INC., PLx Pharma Inc., PLx Pharma Winddown Corp.